Our hypothesis is further strengthened by the recent approval of checkpoint inhibitors in breast cancer with high PD-L1 expression on immune cells [37], further highlighting that immune-mediated pathways are crucial and present an excellent opportunity for targeted approaches to overcome underlying immunosuppression in breast cancer and improve outcomes. Here, CD274 is linked to breast cancer.